A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ghayas Issa, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Johns Hopkins University
Baltimore, Maryland, United States
Recruiting - Dana-Farber Cancer Center
Boston, Massachusetts, United States
Recruiting - Memorial Sloan Kettering Cancer Center
New York, New York, United States
Aaron Goldberg, MDRecruiting - Md Anderson Cancer Center
Houston, Texas, United States
Ghayas Issa, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Sept 2024
- Primary completion
- 30 Dec 2026
- Completion
- 30 Dec 2028
- Last update posted
- 13 Apr 2026
- Registered enrollment
- 8
- Registry id
- NCT06284486
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.